Analysed SAVARA INC (SVRA:NASDAQ) News Sources
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
18-05-2026
yahoo.com
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
19-05-2026
yahoo.com
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
20-05-2026
yahoo.com
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
23-05-2026
fool.com
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
27-05-2026
yahoo.com
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
08-06-2026
yahoo.com
What is the current price of SAVARA INC (SVRA:NASDAQ)?
The current price of SAVARA INC (SVRA:NASDAQ) is $5.27.
SAVARA INC (SVRA:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAVARA INC (SVRA:NASDAQ) since the previous trading day is $0.
SAVARA INC (SVRA:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAVARA INC (SVRA:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for SAVARA INC (SVRA:NASDAQ)?
The most recent average sentiment score for SAVARA INC (SVRA:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for SAVARA INC (SVRA:NASDAQ)?
The most recent sentiment for SAVARA INC (SVRA:NASDAQ) is .
SEC-8K** Filing Available For SAVARA INC (SVRA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.